by Instem Team | Mar 11, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
Discovery Given that a single high-throughput screening campaign may evaluate over 2 million compounds, discovery teams must move through terabytes of data before deciding to prioritize only a handful of compounds after target identification. When data and rationale...
by Instem Team | Mar 6, 2026 | Clinical, Resources
Open-source software has been increasingly popular in biostatistics and life sciences. While SAS has been the go-to programming language for biostatistics, R and other open-source languages are being utilized more often. R, known for its distinct capabilities and...
by Instem Team | Mar 4, 2026 | In Silico & Data Insights, Regulatory Submission, Study Management
The earliest stages of drug research and development (R&D) generate massive volumes of scientific, operational, and compliance-critical data, often across disconnected tools, teams, and formats. That fragmentation slows decision-making, increases rework, and...
by Instem Team | Mar 3, 2026 | Company News
Instem is pleased to announce the completion of a significant refurbishment of its Stone, UK Headquarters. The revitalisation of the UK Headquarters is a strategic investment reflecting Instem’s commitment to excellence, innovation, and the creation of a modern...
by Instem Team | Mar 3, 2026 | Clinical, Quality System Management, Resources
Organizations today must deliver consistent, high‑quality products and services amid rising customer expectations and increasing regulatory demands. Traditional, reactive inspection methods are no longer enough—modern quality assurance (QA) requires proactive systems...
